Hepato Cellular Carcinoma (HCC)
22
14
14
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
4.5%
1 terminated out of 22 trials
66.7%
-19.9% vs benchmark
14%
3 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (22)
The Impact of Anaesthesia and Sedation on Inflammation and NETosis in Hepatocellular Carcinoma Ablation
Outpatient Versus Inpatient Care Pathway for Intra-arterial Treatment of Primary Liver Cancer (CHOC)
Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With AtezolizUmaB and Bevacizumab
SHIELD: Sorafenib Hand-foot Syndrome Inhibition With Pre-Emptive Local Delivery of Topical Indomethacin
A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma
Becotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular Carcinoma
TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk
Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC
Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resection
Transarterial Chemoembolization (TACE) Plus ABCB1 Inhibition Versus TACE Alone in Patients With Hepatocellular Carcinoma
BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma
Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC
Hepatocellular Carcinoma Identification Using Delta-HLD
Effect and Mechanism of ALPPS Operation on Liver Regeneration
PIVKA-II for Predicting Portal Vein Thrombosis in Hepatocellular Carcinoma
Fibroscan Evaluating Immunotherapy Response in Hepatocellular Carcinoma
Retrospective Clinical Validation of HepatoPredict
Evaluate the Effect of Tirazamine on Primary Liver Cancer.
HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of Recurrence
Ex-vivo Hypotermic Perfusion in Patients with Hepatocellular Carcinoma to Reduce the Incidence of Tumor Recurrence